[{"Assets_0_FY_USD":440248000.0,"CommonStockSharesOutstanding_0_FY_shares":142789000.0,"EarningsPerShareBasic_1_FY_USD":-0.01,"EarningsPerShareBasic_4_FY_USD":-0.56,"NetIncomeLoss_1_FY_USD":-2126000.0,"NetIncomeLoss_4_FY_USD":-80330000.0,"StockholdersEquity_0_FY_USD":248887000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_FY_shares":144203000.0,"WeightedAverageNumberOfSharesOutstandingBasic_4_FY_shares":143599000.0,"Ticker":"HALO","CIK":"1159036","name":"HALOZYME THERAPEUTICS INC","OfficialName":"Halozyme Therapeutics Inc. Common Stock","form":"10-K","period":"20181231","fy":"2018.0","fp":"FY","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"5856719603.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Biological Products (No Diagnostic Substances)","Market":"NASDAQ","SP500":"nan","filed":"20190221"}]